Dofetilide
A Class III antiarrhythmic drug used for the maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter and for the conversion of these arrhythmias to sinus rhythm. It selectively blocks the rapid component of the delayed rectifier potassium current (IKr/hERG), prolonging cardiac action potential duration and the effective refractory period
CAS Number: 115256-11-6
Molecular Mass: 441.6 g/mol
Formula: C19H27N3O5S2
Smiles: CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1
Synonymes:
Dofetilide, 115256-11-6, Tikosyn, Dofetilida, Dofetilidum, UK-68,798, UK-68798, DTXSID5046433, R4Z9X1N2ND, beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide, Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-, CHEBI:4681, DTXCID3026433, N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide, Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-, 1-MSPMPE, N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide, N-(4-(2-(2-(4-methanesulfonamidophenyl)ethyl-methylamino)ethoxy)phenyl)methanesulfonamide, N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide, Dofetilide 0.5mg, N-(4-(2-((2-(4-methanesulfonamidophenoxy)ethyl)(methyl)amino)ethyl)phenyl)methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide, N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide, DOFETILDE, 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane, Dofetilide 0.25mg, Dofetilide 0.125mg, RefChem:57792, C01BD04, Dofetilidum [INN-Latin], Dofetilida [INN-Spanish], UK 68798, N-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide, MFCD00869707, C19H27N3O5S2, CHEMBL473, N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide, 1-(4-Methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane, NCGC00164549-01, Dofetilide (>90%), N-[4-(2-{[2-(4-methanesulfonamidophenyl)ethyl](methyl)amino}ethoxy)phenyl]methanesulfonamide, N-[4-(2-{2-[4-(methanesulphonamido)phenoxyl]-N-methylethylamino}ethyl)phenyl]-methanesulphonamide, Xelide, SMR000466333, Tikosyn (TN), CAS-115256-11-6, UK 68,798, UNII-R4Z9X1N2ND, HSDB 7927, N-[4-[2-[Methyl[2-[4-(methylsulfonamido)phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide, IXTMWRCNAAVVAI-UHFFFAOYSA-N, Dofetilide [USAN:USP:INN:BAN], Dofetilide (Tikosyn), UK68798, Dofetilide (Standard), Dofetilide (Tikosyn)?, DOFETILIDE [MI], DOFETILIDE [INN], DOFETILIDE [JAN], DOFETILIDE [USAN], DOFETILIDE [VANDF], DOFETILIDE [MART.], DOFETILIDE [USP-RS], DOFETILIDE [WHO-DD], SCHEMBL16135, Dofetilide (JAN/USP/INN), MLS000759442, MLS001424185, MLS006010154, DOFETILIDE [EMA EPAR], Dofetilide - Bio-X trade mark, GTPL2604, orb1300735, DOFETILIDE [ORANGE BOOK], Dofetilide, >=98% (HPLC), HY-B0232R, DOFETILIDE [USP MONOGRAPH], GLXC-05217, HMS2051N14, HMS2089F03, HMS2232H19, HMS3261G03, HMS3370B18, HMS3393N14, HMS3655A17, HMS3715H20, HMS5079J08, HY-B0232, Tox21_112178, Tox21_500351, AC-385, BDBM50031720, EBC-11239, HB1078, NSC786034, s1658, AKOS005259921, Tox21_112178_1, CCG-101037, DB00204, FD09968, NC00287, NSC-786034, UK68789, MRF-0000317, N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide, NCGC00164549-02, NCGC00261036-01, BD164377, SY227006, UK 68789, DB-041252, NS00068338, SW197667-2, C07751, D00647, H11953, AB00639976-06, AB00639976-08, AB00639976_09, EN300-19768191, F819018, SR-01000759368, 11W-0619, Q3712521, SR-01000759368-4, BRD-K86887724-001-05-6, BRD-K86887724-001-09-8, BRD-K86887724-001-10-6, Dofetilide, United States Pharmacopeia (USP) Reference Standard, .BETA.-((P-METHANESULFONAMIDOPHENETHYL)METHYLAMINO)METHANESULFONO-P-PHENETIDIDE, 1-(4-Methansulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane, (Dofetilide) N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide, N-(4-{2-[{2-[4-(Methanesulfonamido)phenoxy]ethyl}(methyl)amino]ethyl}phenyl)methanesulfonamide, N-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide, N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide), N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (UK-68798), N-[4-(2-{[2-(4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-METHYL-AMINO}-ETHOXY)-PHENYL]-METHANESULFONAMIDE DOFETILIDE, N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-methanesulfonamide, UK-68798, Tikosyn,
Bioactivity: Class III antiarrhythmic; selective IKr (hERG/Kv11.1) potassium channel blocker
Solubility in Different Solvents
| Solvent | Temperature [K] | Crystal form | Solubility [mg/mL] | Reference |
|---|---|---|---|---|
| 1-Octanol | 293.15 | - | 0.1382 | [493] |
| 1-Octanol | 298.15 | - | 0.1993 | [493] |
| 1-Octanol | 303.15 | - | 0.2797 | [493] |
| 1-Octanol | 308.15 | - | 0.4016 | [493] |
| 1-Octanol | 313.15 | - | 0.5346 | [493] |
| Hexane | 293.15 | - | 0.0011 | [493] |
| Hexane | 298.15 | - | 0.0013 | [493] |
| Hexane | 303.15 | - | 0.0017 | [493] |
| Hexane | 308.15 | - | 0.002 | [493] |
| Hexane | 313.15 | - | 0.0024 | [493] |
Molecule 3D descriptors
| Descriptor | Value |
|---|---|
| PMI1 | 1060.3914 |
| PMI2 | 19898.3417 |
| PMI3 | 20499.4494 |
| NPR1 | 0.0517 |
| NPR2 | 0.9707 |
| RadiusOfGyration | 6.8515 |
| InertialShapeFactor | 0.0009 |
| Eccentricity | 0.9987 |
| Asphericity | 0.8531 |
| SpherocityIndex | 0.0478 |
| PBF | 0.6543 |